Zepbound is the brand name for tirzepatide, a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. If you’re asking about US patent protection for Zepbound (tirzepatide), here’s a concise overview and how you can get exact details.
What to know about US patent protection for tirzepatide
- The core intellectual property typically covers multiple families:
- Composition-of-matter: the tirzepatide peptide itself (and close variants) the company claims as a new chemical entity.
- Methods of use: how tirzepatide can be used to treat conditions such as type 2 diabetes and obesity.
- Formulations and delivery: specific ways the drug is prepared and administered (e.g., injectable formulations).
- Potential combination or manufacturing patents: other related claims around how it’s made or used in combination with other therapies.
- In the US, patent terms generally run 20 years from the earliest nonprovisional filing date, with possible patent-term adjustments (PTAs) that can extend the actual term.
- In addition to patent protection, tirzepatide (as a biologic peptide) enjoys US regulatory exclusivity:
- Biologics Price Competition and Innovation Act (BPCIA) data exclusivity: about 12 years of data protection from the first FDA approval for a given biologic product.
- There can also be indication- or pediatric-related exclusivities that add months/years on top of patent terms.
- Since Zepbound’s active ingredient (tirzepatide) is a peptide/biologic, the 12-year data exclusivity for the initial FDA-approved indication applies in the US, often providing market protection even if some patents expire earlier.
What you can do to get exact, up-to-date details
- Identify the exact patent family and status:
- Look up tirzepatide on Google Patents and then check the US patents and published applications in the Lilly families covering composition, uses, and formulations.
- Use the USPTO Patent Center to check grant status, expiration dates, and any PTA (patent term adjustment) details.
- If you want a precise list right now, I can guide you step-by-step or, with permission, help fetch current records (patent numbers, grant/expansion dates, and status) from those databases.
What I can provide now
- A high-level view: US protection for tirzepatide is built on multiple patent families (composition, uses, and formulations) owned by Lilly, plus strong regulatory exclusivity for biologics (roughly 12 years from first US approval) that protects the product's market even if some patents begin to expire.
- If you want, I can help you locate specific US patent numbers and their status (granted vs. pending, expiration dates, and any PTA) or summarize a particular patent family’s claims.
Would you like me to pull the current US patent numbers and expiration dates for tirzepatide (Zepbound) or focus on a specific aspect (composition-of-matter, use, or formulation patents)? If you’re able to allow me to look things up, I can provide exact references.